




RealRate

PHARMACEUTICAL 2022

Theravance Biopharma Inc
Rank 193 of 471

Theravance
Biopharma
Medicines That Make a Difference



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Theravance Biopharma Inc is the variable Expenses, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 320%, being 45% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	249,870
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	58,587
Liabilities, Non-Current	0
Other Assets	111,292
Other Compr. Net Income	-47
Other Expenses	66,880
Other Liabilities	0
Other Net Income	105,096
Other Revenues	55,311
Property and Equipment	13,657
Research and Development	193,657
Selling, General and Administrative Expense	99,296

Output Variable	Value in 1000 USD
Assets	374,819
Liabilities	58,587
Expenses	359,833
Revenues	55,311
Stockholders Equity	316,232
Net Income	-199,426
Comprehensive Net Income	-199,450
BaseVar	476,846
ECR before Limited Liability	226%
Economic Capital Ratio	320%